Dr. Chapman is a veteran of large and small biotech companies. He is well versed in all aspects of drug discovery, from target selection, validation, screening, hit-to-lead, lead optimization, preclinical testing, candidate selection, and early clinical development. He has worked with small molecules as well as therapeutic antibodies. Mark has led cross-functional teams, established partnerships with CROs, clinicians, and academic groups, and is adept at addressing key questions in a cost-effective manner. He has deep knowledge in oncology and has additional experience in endocrinology and immunology. He holds a BA in genetics (UC Berkeley), a PhD in Biochemistry (University of Arizona), and trained at the Salk Institute. Dr. Chapman actively consults for a number of start-up/small biotech companies. Past clients include Celgene, Aragon Pharmaceuticals, Sanofi Aventis, and Molecular Response.